302 related articles for article (PubMed ID: 32145020)
1. Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T.
Madan RA; Antonarakis ES; Drake CG; Fong L; Yu EY; McNeel DG; Lin DW; Chang NN; Sheikh NA; Gulley JL
J Natl Cancer Inst; 2020 Jun; 112(6):562-573. PubMed ID: 32145020
[TBL] [Abstract][Full Text] [Related]
2. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125
[TBL] [Abstract][Full Text] [Related]
3. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
Sims RB
Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856
[TBL] [Abstract][Full Text] [Related]
4. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
[TBL] [Abstract][Full Text] [Related]
5. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.
Shore ND; Mantz CA; Dosoretz DE; Fernandez E; Myslicki FA; McCoy C; Finkelstein SE; Fishman MN
Cancer Control; 2013 Jan; 20(1):7-16. PubMed ID: 23302902
[TBL] [Abstract][Full Text] [Related]
6. Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival.
Antonarakis ES; Small EJ; Petrylak DP; Quinn DI; Kibel AS; Chang NN; Dearstyne E; Harmon M; Campogan D; Haynes H; Vu T; Sheikh NA; Drake CG
Clin Cancer Res; 2018 Oct; 24(19):4662-4671. PubMed ID: 29858218
[No Abstract] [Full Text] [Related]
7. Cancer immunotherapy: sipuleucel-T and beyond.
Hammerstrom AE; Cauley DH; Atkinson BJ; Sharma P
Pharmacotherapy; 2011 Aug; 31(8):813-28. PubMed ID: 21923608
[TBL] [Abstract][Full Text] [Related]
8. Beyond sipuleucel-T: immune approaches to treating prostate cancer.
Cheng ML; Fong L
Curr Treat Options Oncol; 2014 Mar; 15(1):115-26. PubMed ID: 24402184
[TBL] [Abstract][Full Text] [Related]
9. Sipuleucel-T: in metastatic castration-resistant prostate cancer.
Plosker GL
Drugs; 2011 Jan; 71(1):101-8. PubMed ID: 21175243
[TBL] [Abstract][Full Text] [Related]
10. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.
Schellhammer PF; Chodak G; Whitmore JB; Sims R; Frohlich MW; Kantoff PW
Urology; 2013 Jun; 81(6):1297-302. PubMed ID: 23582482
[TBL] [Abstract][Full Text] [Related]
11. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
Di Lorenzo G; Ferro M; Buonerba C
BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289
[TBL] [Abstract][Full Text] [Related]
12. Sipuleucel-T for prostate cancer: the immunotherapy era has commenced.
Buonerba C; Ferro M; Di Lorenzo G
Expert Rev Anticancer Ther; 2011 Jan; 11(1):25-8. PubMed ID: 21166508
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer.
Twardowski P; Wong JYC; Pal SK; Maughan BL; Frankel PH; Franklin K; Junqueira M; Prajapati MR; Nachaegari G; Harwood D; Agarwal N
Cancer Treat Res Commun; 2019; 19():100116. PubMed ID: 30682445
[TBL] [Abstract][Full Text] [Related]
14. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Kantoff PW; Higano CS; Shore ND; Berger ER; Small EJ; Penson DF; Redfern CH; Ferrari AC; Dreicer R; Sims RB; Xu Y; Frohlich MW; Schellhammer PF;
N Engl J Med; 2010 Jul; 363(5):411-22. PubMed ID: 20818862
[TBL] [Abstract][Full Text] [Related]
15. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer.
Sheikh NA; Petrylak D; Kantoff PW; Dela Rosa C; Stewart FP; Kuan LY; Whitmore JB; Trager JB; Poehlein CH; Frohlich MW; Urdal DL
Cancer Immunol Immunother; 2013 Jan; 62(1):137-47. PubMed ID: 22865266
[TBL] [Abstract][Full Text] [Related]
16. Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
Dawson NA; Roesch EE
Expert Opin Biol Ther; 2014 May; 14(5):709-19. PubMed ID: 24620782
[TBL] [Abstract][Full Text] [Related]
17. Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome.
GuhaThakurta D; Sheikh NA; Fan LQ; Kandadi H; Meagher TC; Hall SJ; Kantoff PW; Higano CS; Small EJ; Gardner TA; Bailey K; Vu T; DeVries T; Whitmore JB; Frohlich MW; Trager JB; Drake CG
Clin Cancer Res; 2015 Aug; 21(16):3619-30. PubMed ID: 25649018
[TBL] [Abstract][Full Text] [Related]
18. Sipuleucel-T: Prototype for development of anti-tumor vaccines.
Carballido E; Fishman M
Curr Oncol Rep; 2011 Apr; 13(2):112-9. PubMed ID: 21243538
[TBL] [Abstract][Full Text] [Related]
19. Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine.
Wargowski E; Johnson LE; Eickhoff JC; Delmastro L; Staab MJ; Liu G; McNeel DG
J Immunother Cancer; 2018 Mar; 6(1):21. PubMed ID: 29534736
[TBL] [Abstract][Full Text] [Related]
20. The evolving role of immunotherapy in prostate cancer.
Gerritsen WR
Ann Oncol; 2012 Sep; 23 Suppl 8():viii22-7. PubMed ID: 22918924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
